Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Opinion
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Grand Herald dollar-liquidity note (2026-08-05): Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies. Primary source: original at CNBC Finance (cnbc.com).